Nontuberculous MycobacteriaPhase 4NCT00600769
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
A Phase 4 study testing Clarithromycin in people with Nontuberculous Mycobacteria and Mycobacterium Avium Complex, run by The University of Texas Health Science Center at Tyler at 1 site in United States.
Trial summary
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Nontuberculous Mycobacteria, Mycobacterium Avium Complex
- What is being tested?
- Clarithromycin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 210 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 1991to 18 May 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
- Age 18 years and older
Who cannot join
- History of macrolide allergy
- Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
- Children less than 18 years of age
- If a menstruating female, not pregnant and on adequate birth control
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Texas Health Science Center at Tyler
Tyler, Texas, 75708
About this study
Official title: Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria
Read the detailed description
Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history
- Being tested
- Clarithromycin
- Keywords
- MAC, NTM
- Medical subject headings
- Mycobacterium avium-intracellulare Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ClarithromycinDrug
Also called Biaxin
Dosage dependent on clinical factors such as age, weight and patient-specific health status
| Study group | Role | What they receive |
|---|---|---|
| treatment of MAC and other NTM | Other | Clarithromycin drug given twice daily. Receives: Drug: Clarithromycin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures
neg culture x3( sputum conversion)
Measured: 6 months
Secondary outcomes (1)
Microbiological cultures
neg culture for 1 yr on treatment
Measured: 1yr
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2008 (estimated)
- Study startJan 1991
- Primary completionNov 2006
- Study completion18 May 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nontuberculous MycobacteriaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 210 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of Texas Health Science Center at Tyler
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott
- Responsible party
- Principal investigator, Richard J. Wallace, Jr., M.D., The University of Texas Health Science Center at Tyler
- Investigators
- Richard J Wallace, MD, Principal investigator, UTHSCT
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00600769
- Sponsor's protocol ID
- 263
- Status last verified
- May 2017
- First submitted
- 14 Jan 2008
- Last updated
- 23 May 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
- ClinicalTrials.gov ID
- NCT00600769
- Acronym / sponsor ID
- 263
- Keywords
- MAC, NTM
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 210 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center at TylerUniversity, hospital or other
- Collaborators
- Abbott
- Study start
- Jan 1991 (actual)
- Primary completion
- Nov 2006 (actual)
- Study completion
- 18 May 2017 (actual)
- First posted
- 25 Jan 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria
Detailed description
Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| treatment of MAC and other NTM | Other | Drug: ClarithromycinClarithromycin drug given twice daily. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
- Age 18 years and older
Key exclusion criteria (4 listed)
- History of macrolide allergy
- Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
- Children less than 18 years of age
- If a menstruating female, not pregnant and on adequate birth control
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ClarithromycinAlso: BiaxinDosage dependent on clinical factors such as age, weight and patient-specific health status | Drug | treatment of MAC and other NTM |
Primary outcome
Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures
Time frame: 6 months
neg culture x3( sputum conversion)
1 secondary outcome
Microbiological cultures
Time frame: 1yr
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2017.
- Individual participant dataSharing planned: No
Related trials for Nontuberculous Mycobacteria
RecruitingObservational study
Study of Mycobacterial Infections
Mycobacterium Infections
Not yet recruitingPhase 2
Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)
Leprosy, Multibacillary
Enrolling by invitationObservational study
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Active, not recruitingObservational study
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Nontuberculous Mycobacteria, Mycobacterium Tuberculosis
RecruitingPhase 2
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard J Wallace, MD principal investigator
UTHSCT
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Clarithromycin in people with Nontuberculous Mycobacteria and Mycobacterium Avium Complex, run by The University of Texas Health Science Center at Tyler at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2017.